Plain-English translation of NCT06518564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two experimental drugs — and — can help treat endometrial cancer that has come back or spread after patients have already received immunotherapy. has been approved by the FDA for other conditions, but is brand new and has never been tested in patients before. The study will enroll about 25 people and track how well the treatment works and what side effects occur.
Endometrial cancer that returns or spreads after immunotherapy is very difficult to treat, and patients need new options. This trial exists to see if this combination of medications can help patients whose cancer has a specific genetic change called an ARID1A mutation, which may make these drugs work better.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly over about 2 years of treatment, taking one medication daily on certain days and receiving another medication by injection three times per cycle (every 6 weeks). You'll have CT or MRI scans every 3 months, blood tests, urine tests, and heart monitoring (EKG) at various visits. After treatment ends, you'll have follow-up visits at 30 days, 90 days, and then every 6 months for up to 3 years to see how you're doing.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States